A Phase 2a, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Subjects

Trial Profile

A Phase 2a, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2016

At a glance

  • Drugs JNJ 53718678 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Sponsors Janssen Sciences Ireland UC
  • Most Recent Events

    • 30 Oct 2016 Results assessing efficacy presented at the IDWeek 2016
    • 24 Nov 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 11 Sep 2015 Planned number of patients changed from 74 to 78 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top